Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016 - GlobalData

Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016

Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016 - GlobalData
Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016
Published Sep 14, 2016
402 pages — Published Sep 14, 2016
Price US$ 4,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's Medical Devices sector report, Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016' provides an overview of Injectable Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Injectable Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Injectable Drug Delivery under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Injectable Drug Delivery and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Injectable Drug Delivery under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

  
Source:
Document ID
GDME0223EPD
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents220
  1.1 List of Tables138
  1.2 List of Figures211
2 Introduction221
  2.1 Injectable Drug Delivery Overview221
3 Products under Development236
  3.1 Injectable Drug Delivery - Pipeline Products by Stage of Development231
  3.2 Injectable Drug Delivery - Pipeline Products by Segment241
  3.3 Injectable Drug Delivery - Pipeline Products by Territory251
  3.4 Injectable Drug Delivery - Pipeline Products by Regulatory Path261
  3.5 Injectable Drug Delivery - Pipeline Products by Estimated Approval Date271
  3.6 Injectable Drug Delivery - Ongoing Clinical Trials281
4 Injectable Drug Delivery - Pipeline Products under Development by Companies298
  4.1 Injectable Drug Delivery Companies - Pipeline Products by Stage of Development294
  4.2 Injectable Drug Delivery - Pipeline Products by Stage of Development334
5 Injectable Drug Delivery Companies and Product Overview37146
  5.1 Aciont Inc. Company Overview371
    5.1.1 Aciont Inc. Pipeline Products &Ongoing Clinical Trials Overview372
  5.2 Actavis Inc. Company Overview391
    5.2.1 Actavis Inc. Pipeline Products &Ongoing Clinical Trials Overview391
  5.3 AdrenaCard, Inc. Company Overview401
    5.3.1 AdrenaCard, Inc. Pipeline Products &Ongoing Clinical Trials Overview401
  5.4 Allergan, Inc. Company Overview411
    5.4.1 Allergan, Inc. Pipeline Products &Ongoing Clinical Trials Overview411
  5.5 Alsensa ApS Company Overview421
    5.5.1 Alsensa ApS Pipeline Products &Ongoing Clinical Trials Overview421
  5.6 AMAG Pharmaceuticals, Inc. Company Overview431
    5.6.1 AMAG Pharmaceuticals, Inc. Pipeline Products &Ongoing Clinical Trials Overview432
  5.7 Amgen Inc. Company Overview451
    5.7.1 Amgen Inc. Pipeline Products &Ongoing Clinical Trials Overview452
  5.8 Antares Pharma, Inc. Company Overview471
    5.8.1 Antares Pharma, Inc. Pipeline Products &Ongoing Clinical Trials Overview476
  5.9 Anterion Therapeutics, Inc. (Inactive) Company Overview531
    5.9.1 Anterion Therapeutics, Inc. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview533
  5.10 Arnali, LLC Company Overview561
    5.10.1 Arnali, LLC Pipeline Products &Ongoing Clinical Trials Overview561
  5.11 Artemes Technologies, Inc. Company Overview571
    5.11.1 Artemes Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview571
  5.12 AstraZeneca Plc Company Overview581
    5.12.1 AstraZeneca Plc Pipeline Products &Ongoing Clinical Trials Overview582
  5.13 Atanse, Inc. Company Overview601
    5.13.1 Atanse, Inc. Pipeline Products &Ongoing Clinical Trials Overview602
  5.14 AzureBio, S.L. Company Overview621
    5.14.1 AzureBio, S.L. Pipeline Products &Ongoing Clinical Trials Overview621
  5.15 Becton, Dickinson and Company Company Overview631
    5.15.1 Becton, Dickinson and Company Pipeline Products &Ongoing Clinical Trials Overview634
  5.16 Bespak Europe Ltd. Company Overview671
    5.16.1 Bespak Europe Ltd. Pipeline Products &Ongoing Clinical Trials Overview673
  5.17 Biodel Inc. Company Overview701
    5.17.1 Biodel Inc. Pipeline Products &Ongoing Clinical Trials Overview702
  5.18 BioMarin Pharmaceutical Inc. Company Overview721
    5.18.1 BioMarin Pharmaceutical Inc. Pipeline Products &Ongoing Clinical Trials Overview722
  5.19 BioRestorative Therapies, Inc. Company Overview741
    5.19.1 BioRestorative Therapies, Inc. Pipeline Products &Ongoing Clinical Trials Overview742
  5.20 Boston University Company Overview761
    5.20.1 Boston University Pipeline Products &Ongoing Clinical Trials Overview761
  5.21 BTG Plc Company Overview771
    5.21.1 BTG Plc Pipeline Products &Ongoing Clinical Trials Overview772
  5.22 Burke Pharmaceuticals, LLC Company Overview791
    5.22.1 Burke Pharmaceuticals, LLC Pipeline Products &Ongoing Clinical Trials Overview791
  5.23 Callisyn Biomedical Inc Company Overview801
    5.23.1 Callisyn Biomedical Inc Pipeline Products &Ongoing Clinical Trials Overview803
  5.24 Cambridge Consultants Limited Company Overview831
    5.24.1 Cambridge Consultants Limited Pipeline Products &Ongoing Clinical Trials Overview831
  5.25 Case Western Reserve University Company Overview841
    5.25.1 Case Western Reserve University Pipeline Products &Ongoing Clinical Trials Overview841
  5.26 Cincinnati Children's Hospital Medical Center Company Overview851
    5.26.1 Cincinnati Children's Hospital Medical Center Pipeline Products &Ongoing Clinical Trials Overview851
  5.27 Clearside BioMedical, Inc. Company Overview861
    5.27.1 Clearside BioMedical, Inc. Pipeline Products &Ongoing Clinical Trials Overview864
  5.28 Consort Medical plc Company Overview901
    5.28.1 Consort Medical plc Pipeline Products &Ongoing Clinical Trials Overview901
  5.29 Credence MedSystems, Inc. Company Overview911
    5.29.1 Credence MedSystems, Inc. Pipeline Products &Ongoing Clinical Trials Overview911
  5.30 CrossCoat Medical LLC Company Overview921
    5.30.1 CrossCoat Medical LLC Pipeline Products &Ongoing Clinical Trials Overview921
  5.31 Cytosial Biomedic, S.a.s. Company Overview931
    5.31.1 Cytosial Biomedic, S.a.s. Pipeline Products &Ongoing Clinical Trials Overview931
  5.32 DALI Medical Devices Ltd. Company Overview941
    5.32.1 DALI Medical Devices Ltd. Pipeline Products &Ongoing Clinical Trials Overview944
  5.33 Delcath Systems, Inc. Company Overview981
    5.33.1 Delcath Systems, Inc. Pipeline Products &Ongoing Clinical Trials Overview985
  5.34 DelSite, Inc. (Inactive) Company Overview1031
    5.34.1 DelSite, Inc. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview1031
  5.35 Elcam Medical Company Overview1041
    5.35.1 Elcam Medical Pipeline Products &Ongoing Clinical Trials Overview1044
  5.36 EmboMedics Company Overview1081
    5.36.1 EmboMedics Pipeline Products &Ongoing Clinical Trials Overview1081
  5.37 Emergent BioSolutions Inc. Company Overview1091
    5.37.1 Emergent BioSolutions Inc. Pipeline Products &Ongoing Clinical Trials Overview1092
  5.38 Eveon SAS Company Overview1111
    5.38.1 Eveon SAS Pipeline Products &Ongoing Clinical Trials Overview1111
  5.39 Ghent University Company Overview1121
    5.39.1 Ghent University Pipeline Products &Ongoing Clinical Trials Overview1121
  5.40 Hannover Medical School Company Overview1131
    5.40.1 Hannover Medical School Pipeline Products &Ongoing Clinical Trials Overview1131
  5.41 Indian Institute of Science Company Overview1141
    5.41.1 Indian Institute of Science Pipeline Products &Ongoing Clinical Trials Overview1141
  5.42 Inovio Pharmaceuticals, Inc. Company Overview1151
    5.42.1 Inovio Pharmaceuticals, Inc. Pipeline Products &Ongoing Clinical Trials Overview1152
  5.43 LyoGo Company Overview1171
    5.43.1 LyoGo Pipeline Products &Ongoing Clinical Trials Overview1171
  5.44 Medicom Innovation Partner a/s Company Overview1181
    5.44.1 Medicom Innovation Partner a/s Pipeline Products &Ongoing Clinical Trials Overview1181
  5.45 Meridian Medical Technologies, Inc. Company Overview1191
    5.45.1 Meridian Medical Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview1191
  5.46 Mertiva AB Company Overview1201
    5.46.1 Mertiva AB Pipeline Products &Ongoing Clinical Trials Overview1201
  5.47 Microchips Biotech, Inc. Company Overview1211
    5.47.1 Microchips Biotech, Inc. Pipeline Products &Ongoing Clinical Trials Overview1212
  5.48 Midatech Pharma Plc Company Overview1231
    5.48.1 Midatech Pharma Plc Pipeline Products &Ongoing Clinical Trials Overview1232
  5.49 Milestone Scientific Inc. Company Overview1251
    5.49.1 Milestone Scientific Inc. Pipeline Products &Ongoing Clinical Trials Overview1253
  5.50 North Carolina State University Company Overview1281
    5.50.1 North Carolina State University Pipeline Products &Ongoing Clinical Trials Overview1282
  5.51 Ocelus Company Overview1301
    5.51.1 Ocelus Pipeline Products &Ongoing Clinical Trials Overview1301
  5.52 Oval Medical Technologies Limited Company Overview1311
    5.52.1 Oval Medical Technologies Limited Pipeline Products &Ongoing Clinical Trials Overview1311
  5.53 Particle Therapeutics Ltd Company Overview1321
    5.53.1 Particle Therapeutics Ltd Pipeline Products &Ongoing Clinical Trials Overview1321
  5.54 Pfizer Inc. Company Overview1331
    5.54.1 Pfizer Inc. Pipeline Products &Ongoing Clinical Trials Overview1332
  5.55 Portal Instruments, Inc. Company Overview1351
    5.55.1 Portal Instruments, Inc. Pipeline Products &Ongoing Clinical Trials Overview1351
  5.56 pSivida Corp. Company Overview1361
    5.56.1 pSivida Corp. Pipeline Products &Ongoing Clinical Trials Overview1365
  5.57 Ratio, Inc. Company Overview1411
    5.57.1 Ratio, Inc. Pipeline Products &Ongoing Clinical Trials Overview1412
  5.58 Recon Therapeutics, LLC Company Overview1431
    5.58.1 Recon Therapeutics, LLC Pipeline Products &Ongoing Clinical Trials Overview1431
  5.59 Replenish Inc Company Overview1441
    5.59.1 Replenish Inc Pipeline Products &Ongoing Clinical Trials Overview1442
  5.60 RepliCel Life Sciences, Inc. Company Overview1461
    5.60.1 RepliCel Life Sciences, Inc. Pipeline Products &Ongoing Clinical Trials Overview1461
  5.61 RetinaPharma Technologies, Inc. Company Overview1471
    5.61.1 RetinaPharma Technologies, Inc. Pipeline Products &Ongoing Clinical Trials Overview1471
  5.62 Rx Safes, Inc. Company Overview1481
    5.62.1 Rx Safes, Inc. Pipeline Products &Ongoing Clinical Trials Overview1481
  5.63 Scandinavian Health Ltd Company Overview1491
    5.63.1 Scandinavian Health Ltd Pipeline Products &Ongoing Clinical Trials Overview1491
  5.64 Shire Plc Company Overview1501
    5.64.1 Shire Plc Pipeline Products &Ongoing Clinical Trials Overview1502
  5.65 Spine Smith, LP Company Overview1521
    5.65.1 Spine Smith, LP Pipeline Products &Ongoing Clinical Trials Overview1521
  5.66 Sun Pharmaceutical Industries Limited Company Overview1531
    5.66.1 Sun Pharmaceutical Industries Limited Pipeline Products &Ongoing Clinical Trials Overview1532
  5.67 TCB medical devices Company Overview1551
    5.67.1 TCB medical devices Pipeline Products &Ongoing Clinical Trials Overview1551
  5.68 Teva Pharmaceutical Industries Ltd. Company Overview1561
    5.68.1 Teva Pharmaceutical Industries Ltd. Pipeline Products &Ongoing Clinical Trials Overview1562
  5.69 Texas Tech University Company Overview1581
    5.69.1 Texas Tech University Pipeline Products &Ongoing Clinical Trials Overview1581
  5.70 TheraKine Ltd. (Inactive) Company Overview1591
    5.70.1 TheraKine Ltd. (Inactive) Pipeline Products &Ongoing Clinical Trials Overview1592
  5.71 Unilife Corporation Company Overview1611
    5.71.1 Unilife Corporation Pipeline Products &Ongoing Clinical Trials Overview1613
  5.72 United Therapeutics Corporation Company Overview1641
    5.72.1 United Therapeutics Corporation Pipeline Products &Ongoing Clinical Trials Overview1642
  5.73 University College London Company Overview1661
    5.73.1 University College London Pipeline Products &Ongoing Clinical Trials Overview1661
  5.74 University of Auckland Company Overview1671
    5.74.1 University of Auckland Pipeline Products &Ongoing Clinical Trials Overview1671
  5.75 University of Calgary Company Overview1681
    5.75.1 University of Calgary Pipeline Products &Ongoing Clinical Trials Overview1681
  5.76 University of California, Irvine Company Overview1691
    5.76.1 University of California, Irvine Pipeline Products &Ongoing Clinical Trials Overview1691
  5.77 University of California, San Diego Company Overview1701
    5.77.1 University of California, San Diego Pipeline Products &Ongoing Clinical Trials Overview1701
  5.78 University of California, San Francisco Company Overview1711
    5.78.1 University of California, San Francisco Pipeline Products &Ongoing Clinical Trials Overview1711
  5.79 University of Delaware Company Overview1721
    5.79.1 University of Delaware Pipeline Products &Ongoing Clinical Trials Overview1721
  5.80 University of Dundee Company Overview1731
    5.80.1 University of Dundee Pipeline Products &Ongoing Clinical Trials Overview1731
  5.81 University of Florida Company Overview1741
    5.81.1 University of Florida Pipeline Products &Ongoing Clinical Trials Overview1743
  5.82 University of Missouri Company Overview1771
    5.82.1 University of Missouri Pipeline Products &Ongoing Clinical Trials Overview1771
  5.83 University of Saskatchewan Company Overview1781
    5.83.1 University of Saskatchewan Pipeline Products &Ongoing Clinical Trials Overview1781
  5.84 University of Texas at Austin Company Overview1791
    5.84.1 University of Texas at Austin Pipeline Products &Ongoing Clinical Trials Overview1792
  5.85 Urodelia SA Company Overview1811
    5.85.1 Urodelia SA Pipeline Products &Ongoing Clinical Trials Overview1811
  5.86 Vanderbilt University Company Overview1821
    5.86.1 Vanderbilt University Pipeline Products &Ongoing Clinical Trials Overview1821
6 Injectable Drug Delivery- Recent Developments183216
  6.1 Aug 29, 2016: Mylan to Launch First Generic to EpiPen Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product1831
  6.2 Aug 29, 2016: pSivida Announces 13 New Patents Issued or Allowed1841
  6.3 Aug 29, 2016: Catalent Reports Fourth Quarter and Fiscal Year 2016 Results1843
  6.4 Aug 25, 2016: Mylan Taking Immediate Action To Further Enhance Access To EpiPen (Epinephrine Injection, USP) Auto-Injector1871
  6.5 Aug 25, 2016: Medtronic Reports First Quarter Financial Results1882
  6.6 Aug 24, 2016: Senators Ask FDA to Account for Any Alternatives to the EpiPen Amid Product Cost Increases1901
  6.7 Aug 24, 2016: Hillary Clinton Statement on EpiPen Pricing1911
  6.8 Aug 24, 2016: Milestone Scientific Begins Transition From a Product Development to a Business Development Company1911
  6.9 Aug 22, 2016: Mylan's Commitment to EpiPen (epinephrine injection, USP) Auto-Injector Access1921
  6.10 Aug 17, 2016: Consort Medical Announces Directorate Change1931
  6.11 Aug 16, 2016: Delcath Announces Second Quarter Financial Results1941
  6.12 Aug 15, 2016: MRI Interventions Announces 2016 Second Quarter and Six Month Results1954
  6.13 Aug 12, 2016: Milestone Scientific Reports 34% Increase in Revenue for the Second Quarter of 20161991
  6.14 Aug 11, 2016: Biodel Reports Third Quarter Fiscal Year 2016 Financial Results2001
  6.15 Aug 11, 2016: Clearside Biomedical Reports Second Quarter 2016 Financial Results2001
  6.16 Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle2011
  6.17 Aug 09, 2016: BioMarin Pharma Prices Public Offering of Shares for USD720 Million2021
  6.18 Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%2023
  6.19 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results2052
  6.20 Aug 09, 2016: Halozyme Reports Second Quarter 2016 Financial Results2071
  6.21 Aug 05, 2016: Caverion delivers a Large Project for Novo Nordisk s new insulin production facility in Hillerod, Denmark2081
  6.22 Aug 05, 2016: Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 20162091
  6.23 Aug 04, 2016: Teva Reports Second Quarter 2016 Results2095
  6.24 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter2141
  6.25 Aug 04, 2016: Merck Lifts Forecast Following Good Second Quarter2153
  6.26 Aug 04, 2016: Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results2183
  6.27 Aug 03, 2016: pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer2211
  6.28 Aug 02, 2016: Merck and Allergan May Acquire Biogen2211
  6.29 Aug 02, 2016: Pfizer Reports Second-Quarter 2016 Results2214
  6.30 Aug 02, 2016: Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook2255
  6.31 Aug 01, 2016: BCWorld Pharm Raises USD1.8 Million in Private Placement of Shares2301
  6.32 Aug 01, 2016: Aptevo Therapeutics Completes Separation from Emergent BioSolutions2301
  6.33 Aug 01, 2016: Clearside Biomedical Announces Promotion of Glenn Noronha, Ph.D. to Chief Scientific Officer and Jennifer M. Kissner, Ph.D. to Vice President, Clinical Development2301
  6.34 Aug 01, 2016: Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics2311
  6.35 Jul 29, 2016: Adamis Pharma to Raise USD11 Million in Private Placement of Units2311
  6.36 Jul 29, 2016: Sanofi Announces Q2 2016 Results2327
  6.37 Jul 29, 2016: Royalty report for Q2 2016 and update on lixisenatide (Lyxumia/Adlyxin) and iGlarLixi2391
  6.38 Jul 28, 2016: BioCorRx Enters into Licensing Agreement with Therakine2401
  6.39 Jul 28, 2016: Unilife Announces New Leadership Team and Targeted Growth Strategy2402
  6.40 Jul 28, 2016: Alkermes Reports Second Quarter 2016 Financial Results2422
  6.41 Jul 28, 2016: West Announces Second Quarter 2016 Results2442
  6.42 Jul 28, 2016: United Therapeutics Reports Second Quarter 2016 Financial Results2461
  6.43 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors2471
  6.44 Jul 28, 2016: AstraZeneca: H1 2016 Results24712
  6.45 Jul 27, 2016: Marathon Pharmaceuticals Names Two New Executive Team Members2591
  6.46 Jul 26, 2016: Dr. Reddy s Q1 FY17 Financial Results2601
  6.47 Jul 21, 2016: Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 20182611
  6.48 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 20252621
  6.49 Jul 21, 2016: Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 20222621
  6.50 Jul 21, 2016: Biogen Reports Second Quarter 2016 Revenues of $2.9 Billion2632
  6.51 Jul 20, 2016: Milestone Scientific Files 510(k) Application for Marketing Clearance of the Epidural Instrument and Disposables in the United States2651
  6.52 Jul 20, 2016: Data Shows pSivida's Tethadur Provides Prolonged, Sustained Release of Avastin With High Drug Efficacy2661
  6.53 Jul 19, 2016: MilliporeSigma Starts Construction on $115 Million Multi-faceted Life Science Campus in Burlington, Massachusetts2671
  6.54 Jul 18, 2016: Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 20162671
  6.55 Jul 18, 2016: Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 20262681
  6.56 Jul 18, 2016: Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 20182681
  6.57 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 20212691
  6.58 Jul 18, 2016: Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 20232691
  6.59 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 20462701
  6.60 Jul 18, 2016: Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 20192701
  6.61 Jul 18, 2016: Unilife Submits Plan to Regain Compliance with NASDAQ Requirements2711

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Injectable-Drug-Delivery-Medical-Devices-Pipeline-Assessment-2016-2085-23614>
  
APA:
GlobalData. (2016). Injectable Drug Delivery - Medical Devices Pipeline Assessment, 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Injectable-Drug-Delivery-Medical-Devices-Pipeline-Assessment-2016-2085-23614>
  
US$ 4,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.